Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions
Does insulin resistance influence neurodegeneration in non-diabetic Alzheimers subjects
Their effectiveness is reduced without physical activity
Frequency: as needed before bed
Red flags requiring urgent medical attention include severe, persistent abdominal pain (which may radiate to the back), repeated vomiting, inability to keep fluids down, or reduced urine output
It is involved in the regulation of cell proliferation, differentiation, and survival, and is closely linked to the suppression of postmitotic neuron-specific growth
